InvestorsHub Logo
Followers 831
Posts 120054
Boards Moderated 17
Alias Born 09/05/2002

Re: NY1972 post# 1165

Wednesday, 10/28/2015 9:40:21 AM

Wednesday, October 28, 2015 9:40:21 AM

Post# of 3022
A few comments:

1. Each HCV regimen has to be considered on its own merits.

2. Not all members of the same HCV drug class have similar efficacy and safety.

3. We do not know that the PI component in V-Pak was the cause of the FDA label revision.

4. ABBV/ENTA's second-generation regimen (ABT-493/ABT-530) consists of a PI and an NS5A; however (unlike V-Pak), the PI in ABBV/ENTA's second-generation regimen is not boosted with ritonavir.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ENTA News